Higher levels of a single blood protein can flag which cognitively healthy older adults are most likely to develop cognitive impairment years later, according to a study published in the Journal of the American Medical Association. Researchers pooled data from six international cohorts totaling 2,684 participants, all of them unimpaired at the outset, and found that baseline concentrations of plasma phosphorylated tau 217 - p-tau217 - tracked with rising risk of clinical progression over both five and ten years.
What gives the finding weight is what the researchers accounted for. The association between p-tau217 and later impairment held after adjusting for APOE e4 carrier status, the best-known genetic risk factor for Alzheimer's disease, and for amyloid PET imaging, currently among the most established ways to detect Alzheimer's pathology in the brain. In other words, the blood measure appeared to carry prognostic information beyond what genetics and brain scans already provide.
That matters most for the presymptomatic window, the stretch of years when Alzheimer's-related changes are accumulating but nothing has gone visibly wrong. A simple blood draw that helps sort who is on a faster trajectory would make it far easier to build risk prediction models and to enroll the right participants in trials of preclinical Alzheimer's treatments, where testing drugs on people who will never progress dilutes any signal a therapy might produce.
The authors are explicit that this is not yet a screening test. The cohorts studied were selected rather than broadly representative, and p-tau217 assays still lack agreed cutoff values that would let a clinician translate one person's number into an individual prognosis. Validation in unselected, real-world populations and assay-specific thresholds both need to come first.